Physician profile
Shahnaz Fatteh
NPI 1588632533
$676,589.13
in general payments reported to CMS, 2019-2025
45 companies · $144K in 2025
The $144K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $24K · 2021: $60K · 2022: $115K · 2023: $151K · 2024: $100K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $244K · Consulting Fee: $87K · Travel and Lodging: $36K · Food and Beverage: $25K · Honoraria: $3,647 · Education: $37.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $243,600.30 |
| Consulting Fee | $87,053.57 |
| Travel and Lodging | $35,905.58 |
| Food and Beverage | $24,962.80 |
| Honoraria | $3,647.00 |
| Education | $37.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $293,213.61 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pharming Healthcare, INC. | $137,198.43 | 2019-2025 | Ruconest, Joenja |
| Astrazeneca Pharmaceuticals Lp | $102,546.36 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Incyte Corporation | $21,135.82 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $19,835.51 | 2019-2025 | Dupixent |
| Genzyme Corporation | $16,991.35 | 2020-2025 | |
| Optinose US, INC. | $15,774.00 | 2019-2025 | |
| Ionis Pharmaceuticals, INC. | $13,396.75 | 2025 | Dawnzera |
| Hikma Pharmaceuticals USA | $11,036.89 | 2023-2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $9,410.12 | 2019-2025 | |
| Csl Behring | $8,757.36 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Amgen INC. | $5,411.78 | 2019-2025 | Tezspire, Otezla, Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $5,323.71 | 2020-2025 | Takhzyro, Cuvitru, Glassia |
| Blueprint Medicines Corporation | $5,235.83 | 2023-2025 | Ayvakit |
| Alk-Abello, INC | $2,520.45 | 2019-2024 | Odactra, Ragwitek, Grastek |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,345.77 | 2022 | |
| Kaleo, INC. | $1,255.31 | 2019-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $875.04 | 2021-2025 | Orladeyo |
| Octapharma USA, INC. | $852.15 | 2019-2024 | Cutaquig, Panzyga |
| Pfizer INC. | $756.01 | 2019-2025 | |
| Galderma Laboratories, L.P. | $442.08 | 2025 | Nemluvio |
| Grifols USA, LLC | $409.13 | 2019-2025 | Xembify |
| Aimmune Therapeutics, INC. | $346.68 | 2020-2022 | |
| Adma Biomanufacturing LLC | $337.64 | 2023-2025 | |
| Shire North American Group INC | $247.92 | 2019 | |
| Genentech USA, INC. | $191.40 | 2019-2025 | Xolair |
| Lilly USA, LLC | $191.20 | 2023-2025 | Mounjaro, Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $142.63 | 2025 | Neffy |
| Inspire Medical Systems, INC. | $141.02 | 2025 | Inspire |
| Leo Pharma INC. | $139.00 | 2022-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.93 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $135.03 | 2019-2021 | |
| X4 Pharmaceuticals, INC. | $135.00 | 2024 | Xolremdi |
| Phadia US INC. | $126.98 | 2021-2024 | Immunocap |
| Genentech, INC. | $125.00 | 2024 | Xolair |
| Sanofi US Services INC. | $119.81 | 2025 | |
| Janssen Pharmaceuticals, INC | $105.60 | 2022 | |
| Horizon Therapeutics Plc | $94.66 | 2020-2022 | |
| Biocryst Pharmaceuticals, INC. | $49.23 | 2020 | |
| Merck Sharp & Dohme LLC | $42.96 | 2021-2023 | |
| Cycle Pharmaceuticals INC | $25.26 | 2025 | Sajazir |
| Alnylam Pharmaceuticals INC. | $20.07 | 2020 | |
| Bio Products Laboratory USA, INC. | $12.65 | 2023 | Coagadex, Gammaplex |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahnaz Fatteh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.